Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(02): 72-73
DOI: 10.4103/0971-5851.116178
ORIGINAL ARTICLE

CA-125 and risk of malignancy index for screening for malignancy in fertile aged females with ovarian cyst, which is more cost effectiveness?

Viroj Wiwanitkit
Wiwanitkit House, Bangkhae, Bangkok, Thailand
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Ovarian tumor is a cause of infertility in the fertile-aged women. Also, it can also turns into malignancy and causes deadly outcome. Screening for malignancy is an important management. Aims: The available screening methods that are widely used at present include CA-125 determination and the risk of malignancy index (RMX), which is a combined CA-125 with ultrasonography, determination. Materials and Methods: Here, the author tries to assess cost-effectiveness of both alternative in screening by basic medical economics technique. Statistics: Classical descriptive analysis was used for cost effectiveness calculation. Results: In this work, from the cost-effectiveness analysis, the CA-125 test is more cost-effectiveness than RMX. Conclusion: This reflects that the usage of additional ultrasonography test for increasing the diagnostic activity in screening for ovarian cyst in the fertile aged females in Thailand is still not appropriate.

Keywords

CA-125 - fertility - ovarian cyst - risk of malignancy index


Publication History

Article published online:
20 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Querleu D, Parmentier D, Chevallier L. Ovarian cysts: Strategy and prognosis. Contracept Fertil Sex 1993;21:167-72.
  • 2 Drake J. Diagnosis and management of the adnexal mass. Am Fam Physician 1998;57:2471-6.
  • 3 Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor-a review. Placenta 2008;29 Suppl B:169-77.
  • 4 Teneriello MG, Park RC. Early detection of ovarian cancer. CA Cancer J Clin 1995;45:71-87.
  • 5 Im SS, Gordon AN, Buttin BM, Leath CA 3 rd , Gostout BS, Shah C, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35-41.
  • 6 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
  • 7 Bouzari Z, Yazdani S, Ahmadi MH, Barat S, Kelagar ZS, Kutenaie MJ, et al. Comparison of three malignancy risk indices and CA-125 in the preoperative evaluation of patients with pelvic masses. BMC Res Notes 2011;4:206.
  • 8 Wiwanitkit V. HE4, CA-125, and cystic ovarian mass. J Gynecol Oncol 2012;23:133.